1	New	New	NNP	NNP	_	2	npadvmod	_	_
2	one-week	one-week	JJ	JJ	_	6	amod	_	_
3	,	,	,	,	_	6	punct	_	_
4	low-dose	low-dose	JJ	JJ	_	6	amod	_	_
5	triple	triple	JJ	JJ	_	6	amod	_	_
6	therapy	therapy	NN	NN	_	0	ROOT	_	_
7	for	for	IN	IN	_	6	prep	_	_
8	the	the	DT	DT	_	9	det	_	_
9	treatment	treatment	NN	NN	_	7	pobj	_	_
10	of	of	IN	IN	_	9	prep	_	_
11	duodenal	duodenal	JJ	JJ	_	12	amod	_	_
12	ulcer	ulcer	NN	NN	_	10	pobj	_	_
13	with	with	IN	IN	_	9	prep	_	_
14	Helicobacter	Helicobacter	NNP	NNP	_	16	nn	_	_
15	pylori	pylori	NN	NN	_	16	nn	_	_
16	infection	infection	NN	NN	_	13	pobj	_	_
17	.	.	.	.	_	6	punct	_	_

1	Antimicrobial	antimicrobial	JJ	JJ	_	2	amod	_	_
2	therapy	therapy	NN	NN	_	6	nsubj	_	_
3	is	be	VBZ	VBZ	_	6	cop	_	_
4	the	the	DT	DT	_	6	det	_	_
5	recommended	recommended	JJ	JJ	_	6	amod	_	_
6	treatment	treatment	NN	NN	_	0	ROOT	_	_
7	for	for	IN	IN	_	6	prep	_	_
8	duodenal	duodenal	JJ	JJ	_	9	amod	_	_
9	ulcer	ulcer	NN	NN	_	7	pobj	_	_
10	associated	associate	VBN	VBN	_	9	vmod	_	_
11	with	with	IN	IN	_	10	prep	_	_
12	Helicobacter	Helicobacter	NNP	NNP	_	14	nn	_	_
13	pylori	pylori	NN	NN	_	14	nn	_	_
14	infection	infection	NN	NN	_	11	pobj	_	_
15	.	.	.	.	_	6	punct	_	_

1	The	the	DT	DT	_	2	det	_	_
2	eradication	eradication	NN	NN	_	15	nsubjpass	_	_
3	of	of	IN	IN	_	2	prep	_	_
4	bismuth-based	bismuth-based	JJ	JJ	_	6	amod	_	_
5	triple	triple	JJ	JJ	_	6	amod	_	_
6	therapy	therapy	NN	NN	_	3	pobj	_	_
7	with	with	IN	IN	_	6	prep	_	_
8	bismuth	bismuth	NN	NN	_	9	nn	_	_
9	subcitrate	subcitrate	NN	NN	_	7	pobj	_	_
10	,	,	,	,	_	9	punct	_	_
11	metronidazole	metronidazole	NN	NN	_	9	conj	_	_
12	and	and	CC	CC	_	9	cc	_	_
13	amoxicillin	amoxicillin	NNP	NNP	_	9	conj	_	_
14	is	be	VBZ	VBZ	_	15	auxpass	_	_
15	limited	limit	VBN	VBN	_	0	ROOT	_	_
16	by	by	IN	IN	_	15	prep	_	_
17	low	low	JJ	JJ	_	18	amod	_	_
18	compliance	compliance	NN	NN	_	16	pobj	_	_
19	,	,	,	,	_	18	punct	_	_
20	drug	drug	NN	NN	_	21	nn	_	_
21	resistance	resistance	NN	NN	_	18	conj	_	_
22	and	and	CC	CC	_	18	cc	_	_
23	side-effects	side-effect	NNS	NNS	_	18	conj	_	_
24	.	.	.	.	_	15	punct	_	_

1	Two-week	two-week	JJ	JJ	_	4	amod	_	_
2	proton	proton	NN	NN	_	4	nn	_	_
3	pump	pump	NN	NN	_	4	nn	_	_
4	inhibitor	inhibitor	NN	NN	_	12	nsubj	_	_
5	-LRB-	-lrb-	-LRB-	-LRB-	_	6	punct	_	_
6	PPI	PPI	NNP	NNP	_	4	appos	_	_
7	-RRB-	-rrb-	-RRB-	-RRB-	_	6	punct	_	_
8	-	-	:	:	_	4	punct	_	_
9	based	base	VBN	VBN	_	11	amod	_	_
10	triple	triple	JJ	JJ	_	11	amod	_	_
11	therapy	therapy	NN	NN	_	4	dep	_	_
12	has	have	VBZ	VBZ	_	0	ROOT	_	_
13	a	a	DT	DT	_	16	det	_	_
14	higher	higher	JJR	JJR	_	16	amod	_	_
15	eradication	eradication	NN	NN	_	16	nn	_	_
16	rate	rate	NN	NN	_	12	dobj	_	_
17	but	but	CC	CC	_	12	cc	_	_
18	is	be	VBZ	VBZ	_	19	cop	_	_
19	costly	costly	JJ	JJ	_	12	conj	_	_
20	.	.	.	.	_	12	punct	_	_

1	This	this	DT	DT	_	2	det	_	_
2	study	study	NN	NN	_	4	nsubjpass	_	_
3	was	be	VBD	VBD	_	4	auxpass	_	_
4	designed	design	VBN	VBN	_	0	ROOT	_	_
5	to	to	TO	TO	_	6	aux	_	_
6	compare	compare	VB	VB	_	4	xcomp	_	_
7	the	the	DT	DT	_	8	det	_	_
8	efficacy	efficacy	NN	NN	_	6	dobj	_	_
9	,	,	,	,	_	4	punct	_	_
10	patient	patient	NN	NN	_	11	nn	_	_
11	compliance	compliance	NN	NN	_	4	dobj	_	_
12	and	and	CC	CC	_	11	cc	_	_
13	cost	cost	NN	NN	_	11	conj	_	_
14	of	of	IN	IN	_	13	prep	_	_
15	short-term	short-term	JJ	JJ	_	18	amod	_	_
16	PPI-based	ppi-based	JJ	JJ	_	18	amod	_	_
17	triple	triple	JJ	JJ	_	18	amod	_	_
18	therapy	therapy	NN	NN	_	14	pobj	_	_
19	with	with	IN	IN	_	11	prep	_	_
20	those	those	DT	DT	_	19	pobj	_	_
21	of	of	IN	IN	_	20	prep	_	_
22	bismuth-based	bismuth-based	JJ	JJ	_	24	amod	_	_
23	triple	triple	JJ	JJ	_	24	amod	_	_
24	therapy	therapy	NN	NN	_	21	pobj	_	_
25	.	.	.	.	_	4	punct	_	_

1	Ninety	ninety	CD	CD	_	2	num	_	_
2	patients	patient	NNS	NNS	_	28	dep	_	_
3	with	with	IN	IN	_	2	prep	_	_
4	active	active	JJ	JJ	_	7	amod	_	_
5	duodenal	duodenal	JJ	JJ	_	7	amod	_	_
6	ulcer	ulcer	NN	NN	_	7	nn	_	_
7	disease	disease	NN	NN	_	3	pobj	_	_
8	and	and	CC	CC	_	7	cc	_	_
9	H	h	NN	NN	_	11	nn	_	_
10	pylori	pylori	NN	NN	_	11	nn	_	_
11	infection	infection	NN	NN	_	7	conj	_	_
12	,	,	,	,	_	28	punct	_	_
13	proven	prove	VBN	VBN	_	28	nsubjpass	_	_
14	with	with	IN	IN	_	13	prep	_	_
15	the	the	DT	DT	_	18	det	_	_
16	13C-urea	13c-urea	NN	NN	_	18	nn	_	_
17	breath	breath	NN	NN	_	18	nn	_	_
18	test	test	NN	NN	_	14	pobj	_	_
19	and	and	CC	CC	_	18	cc	_	_
20	CLO	clo	NN	NN	_	21	nn	_	_
21	test	test	NN	NN	_	18	conj	_	_
22	-LRB-	-lrb-	-LRB-	-LRB-	_	25	punct	_	_
23	Campylobacter-like	campylobacter-like	JJ	JJ	_	25	amod	_	_
24	organism	organism	NN	NN	_	25	nn	_	_
25	test	test	NN	NN	_	21	appos	_	_
26	-RRB-	-rrb-	-RRB-	-RRB-	_	25	punct	_	_
27	were	be	VBD	VBD	_	28	auxpass	_	_
28	treated	treat	VBN	VBN	_	0	ROOT	_	_
29	randomly	randomly	RB	RB	_	28	advmod	_	_
30	in	in	IN	IN	_	28	prep	_	_
31	three	three	CD	CD	_	33	num	_	_
32	therapeutic	therapeutic	JJ	JJ	_	33	amod	_	_
33	groups	group	NNS	NNS	_	30	pobj	_	_
34	:	:	:	:	_	33	punct	_	_
35	Group	Group	NNP	NNP	_	36	nn	_	_
36	A	A	NNP	NNP	_	33	dep	_	_
37	,	,	,	,	_	36	punct	_	_
38	DeNol	denol	NN	NN	_	40	nn	_	_
39	120	120	CD	CD	_	40	num	_	_
40	mg	mg	NN	NN	_	36	conj	_	_
41	,	,	,	,	_	36	punct	_	_
42	amoxicillin	amoxicillin	NNP	NNP	_	44	nn	_	_
43	500	500	CD	CD	_	44	num	_	_
44	mg	mg	NN	NN	_	36	conj	_	_
45	and	and	CC	CC	_	36	cc	_	_
46	metronidazole	metronidazole	NN	NN	_	48	nn	_	_
47	250	250	CD	CD	_	48	num	_	_
48	mg	mg	NN	NN	_	36	conj	_	_
49	four	four	CD	CD	_	50	num	_	_
50	times	time	NNS	NNS	_	36	dep	_	_
51	a	a	DT	DT	_	52	det	_	_
52	day	day	NN	NN	_	36	dep	_	_
53	orally	orally	RB	RB	_	52	advmod	_	_
54	for	for	IN	IN	_	52	prep	_	_
55	14	14	CD	CD	_	56	num	_	_
56	days	day	NNS	NNS	_	54	pobj	_	_
57	;	;	:	:	_	36	punct	_	_
58	Group	group	NN	NN	_	59	nn	_	_
59	B	b	NN	NN	_	36	dep	_	_
60	,	,	,	,	_	59	punct	_	_
61	omeprazole	omeprazole	NN	NN	_	63	nn	_	_
62	20	20	CD	CD	_	63	num	_	_
63	mg	mg	NN	NN	_	59	conj	_	_
64	plus	plus	CC	CC	_	59	cc	_	_
65	clarithromycin	clarithromycin	NN	NN	_	67	nn	_	_
66	500	500	CD	CD	_	67	num	_	_
67	mg	mg	NN	NN	_	59	conj	_	_
68	twice	twice	RB	RB	_	70	advmod	_	_
69	a	a	DT	DT	_	70	det	_	_
70	day	day	NN	NN	_	59	tmod	_	_
71	and	and	CC	CC	_	59	cc	_	_
72	amoxicillin	amoxicillin	NNP	NNP	_	74	nn	_	_
73	500	500	CD	CD	_	74	num	_	_
74	mg	mg	NN	NN	_	59	conj	_	_
75	four	four	CD	CD	_	76	num	_	_
76	times	time	NNS	NNS	_	74	npadvmod	_	_
77	a	a	DT	DT	_	78	det	_	_
78	day	day	NN	NN	_	76	npadvmod	_	_
79	for	for	IN	IN	_	59	prep	_	_
80	14	14	CD	CD	_	81	num	_	_
81	days	day	NNS	NNS	_	79	pobj	_	_
82	;	;	:	:	_	36	punct	_	_
83	Group	Group	NNP	NNP	_	84	nn	_	_
84	C	C	NNP	NNP	_	36	dep	_	_
85	,	,	,	,	_	84	punct	_	_
86	omeprazole	omeprazole	NN	NN	_	88	nn	_	_
87	20	20	CD	CD	_	88	num	_	_
88	mg	mg	NN	NN	_	84	appos	_	_
89	,	,	,	,	_	84	punct	_	_
90	clarithromycin	clarithromycin	NN	NN	_	92	nn	_	_
91	250	250	CD	CD	_	92	num	_	_
92	mg	mg	NN	NN	_	84	conj	_	_
93	and	and	CC	CC	_	84	cc	_	_
94	metronidazole	metronidazole	NN	NN	_	96	nn	_	_
95	500	500	CD	CD	_	96	num	_	_
96	mg	mg	NN	NN	_	84	conj	_	_
97	twice	twice	RB	RB	_	99	advmod	_	_
98	a	a	DT	DT	_	99	det	_	_
99	day	day	NN	NN	_	84	tmod	_	_
100	for	for	IN	IN	_	99	prep	_	_
101	seven	seven	CD	CD	_	102	num	_	_
102	days	day	NNS	NNS	_	100	pobj	_	_
103	.	.	.	.	_	28	punct	_	_

1	Nizatidine	nizatidine	NN	NN	_	3	nn	_	_
2	150	150	CD	CD	_	3	num	_	_
3	mg	mg	NN	NN	_	8	nsubjpass	_	_
4	twice	twice	RB	RB	_	6	advmod	_	_
5	a	a	DT	DT	_	6	det	_	_
6	day	day	NN	NN	_	3	npadvmod	_	_
7	was	be	VBD	VBD	_	8	auxpass	_	_
8	given	give	VBN	VBN	_	0	ROOT	_	_
9	continuously	continuously	RB	RB	_	8	advmod	_	_
10	following	follow	VBG	VBG	_	8	prep	_	_
11	the	the	DT	DT	_	12	det	_	_
12	end	end	NN	NN	_	10	pobj	_	_
13	of	of	IN	IN	_	12	prep	_	_
14	anti-H	anti-h	JJ	JJ	_	16	amod	_	_
15	pylori	pylori	NN	NN	_	16	nn	_	_
16	therapy	therapy	NN	NN	_	13	pobj	_	_
17	for	for	IN	IN	_	12	prep	_	_
18	each	each	DT	DT	_	19	det	_	_
19	group	group	NN	NN	_	17	pobj	_	_
20	.	.	.	.	_	8	punct	_	_

1	Two	two	CD	CD	_	2	num	_	_
2	months	month	NNS	NNS	_	3	npadvmod	_	_
3	later	later	RB	RB	_	15	advmod	_	_
4	,	,	,	,	_	15	punct	_	_
5	endoscopy	endoscopy	NN	NN	_	15	nsubjpass	_	_
6	,	,	,	,	_	5	punct	_	_
7	the	the	DT	DT	_	9	det	_	_
8	CLO	CLO	NNP	NNP	_	9	nn	_	_
9	test	test	NN	NN	_	5	conj	_	_
10	and	and	CC	CC	_	5	cc	_	_
11	13C-urea	13c-urea	NN	NN	_	13	nn	_	_
12	breath	breath	NN	NN	_	13	nn	_	_
13	test	test	NN	NN	_	5	conj	_	_
14	were	be	VBD	VBD	_	15	auxpass	_	_
15	repeated	repeat	VBN	VBN	_	0	ROOT	_	_
16	to	to	TO	TO	_	17	aux	_	_
17	assess	assess	VB	VB	_	15	xcomp	_	_
18	the	the	DT	DT	_	20	det	_	_
19	eradication	eradication	NN	NN	_	20	nn	_	_
20	rate	rate	NN	NN	_	17	dobj	_	_
21	of	of	IN	IN	_	20	prep	_	_
22	H	h	NN	NN	_	23	nn	_	_
23	pylori	pylori	NN	NN	_	21	pobj	_	_
24	and	and	CC	CC	_	20	cc	_	_
25	the	the	DT	DT	_	27	det	_	_
26	ulcer-healing	ulcer-healing	JJ	JJ	_	27	amod	_	_
27	rate	rate	NN	NN	_	20	conj	_	_
28	.	.	.	.	_	15	punct	_	_

1	Drug	drug	NN	NN	_	2	nn	_	_
2	tolerance	tolerance	NN	NN	_	4	nsubjpass	_	_
3	was	be	VBD	VBD	_	4	auxpass	_	_
4	evaluated	evaluate	VBN	VBN	_	0	ROOT	_	_
5	by	by	IN	IN	_	4	prep	_	_
6	patients	patient	NNS	NNS	_	5	pobj	_	_
7	themselves	themselves	PRP	PRP	_	6	npadvmod	_	_
8	by	by	IN	IN	_	4	prep	_	_
9	daily	daily	JJ	JJ	_	10	amod	_	_
10	recording	recording	NN	NN	_	8	pobj	_	_
11	of	of	IN	IN	_	10	prep	_	_
12	any	any	DT	DT	_	13	det	_	_
13	side-effects	side-effect	NNS	NNS	_	11	pobj	_	_
14	.	.	.	.	_	4	punct	_	_

1	Eighty-four	eighty-four	CD	CD	_	2	num	_	_
2	patients	patient	NNS	NNS	_	3	nsubj	_	_
3	completed	complete	VBD	VBD	_	0	ROOT	_	_
4	the	the	DT	DT	_	6	det	_	_
5	entire	entire	JJ	JJ	_	6	amod	_	_
6	course	course	NN	NN	_	3	dobj	_	_
7	of	of	IN	IN	_	6	prep	_	_
8	therapy	therapy	NN	NN	_	7	pobj	_	_
9	and	and	CC	CC	_	8	cc	_	_
10	evaluation	evaluation	NN	NN	_	8	conj	_	_
11	for	for	IN	IN	_	8	prep	_	_
12	H	h	NN	NN	_	14	nn	_	_
13	pylori	pylori	NN	NN	_	14	nn	_	_
14	infection	infection	NN	NN	_	11	pobj	_	_
15	.	.	.	.	_	3	punct	_	_

1	The	the	DT	DT	_	5	det	_	_
2	H	h	NN	NN	_	5	nn	_	_
3	pylori	pylori	NN	NN	_	5	nn	_	_
4	eradication	eradication	NN	NN	_	5	nn	_	_
5	rates	rate	NNS	NNS	_	15	nsubj	_	_
6	in	in	IN	IN	_	5	prep	_	_
7	Groups	group	NNS	NNS	_	6	pobj	_	_
8	A	a	DT	DT	_	7	dep	_	_
9	,	,	,	,	_	8	punct	_	_
10	B	b	NN	NN	_	8	conj	_	_
11	and	and	CC	CC	_	8	cc	_	_
12	C	c	NN	NN	_	8	conj	_	_
13	were	be	VBD	VBD	_	15	cop	_	_
14	75	75	CD	CD	_	15	num	_	_
15	%	%	NN	NN	_	0	ROOT	_	_
16	-LRB-	-lrb-	-LRB-	-LRB-	_	17	punct	_	_
17	21/28	21/28	CD	CD	_	15	appos	_	_
18	-RRB-	-rrb-	-RRB-	-RRB-	_	17	punct	_	_
19	,	,	,	,	_	15	punct	_	_
20	93	93	CD	CD	_	21	num	_	_
21	%	%	NN	NN	_	15	conj	_	_
22	-LRB-	-lrb-	-LRB-	-LRB-	_	23	punct	_	_
23	26/28	26/28	CD	CD	_	21	appos	_	_
24	-RRB-	-rrb-	-RRB-	-RRB-	_	23	punct	_	_
25	and	and	CC	CC	_	15	cc	_	_
26	89	89	CD	CD	_	27	num	_	_
27	%	%	NN	NN	_	15	conj	_	_
28	-LRB-	-lrb-	-LRB-	-LRB-	_	29	punct	_	_
29	25/28	25/28	CD	CD	_	27	appos	_	_
30	-RRB-	-rrb-	-RRB-	-RRB-	_	29	punct	_	_
31	,	,	,	,	_	15	punct	_	_
32	respectively	respectively	RB	RB	_	15	advmod	_	_
33	-LRB-	-lrb-	-LRB-	-LRB-	_	35	punct	_	_
34	p	p	NN	NN	_	35	nsubj	_	_
35	=	=	JJ	JJ	_	32	dep	_	_
36	0.466	0.466	CD	CD	_	35	dobj	_	_
37	-RRB-	-rrb-	-RRB-	-RRB-	_	35	punct	_	_
38	.	.	.	.	_	15	punct	_	_

1	The	the	DT	DT	_	4	det	_	_
2	ulcer	ulcer	NN	NN	_	4	nn	_	_
3	healing	healing	NN	NN	_	4	nn	_	_
4	rate	rate	NN	NN	_	7	nsubj	_	_
5	was	be	VBD	VBD	_	7	cop	_	_
6	86	86	CD	CD	_	7	num	_	_
7	%	%	NN	NN	_	0	ROOT	_	_
8	-LRB-	-lrb-	-LRB-	-LRB-	_	9	punct	_	_
9	24/28	24/28	CD	CD	_	7	dep	_	_
10	-RRB-	-rrb-	-RRB-	-RRB-	_	9	punct	_	_
11	in	in	IN	IN	_	7	prep	_	_
12	Group	Group	NNP	NNP	_	13	nn	_	_
13	A	A	NNP	NNP	_	11	pobj	_	_
14	and	and	CC	CC	_	7	cc	_	_
15	89	89	CD	CD	_	16	num	_	_
16	%	%	NN	NN	_	7	conj	_	_
17	-LRB-	-lrb-	-LRB-	-LRB-	_	18	punct	_	_
18	25/28	25/28	CD	CD	_	16	appos	_	_
19	-RRB-	-rrb-	-RRB-	-RRB-	_	18	punct	_	_
20	in	in	IN	IN	_	16	prep	_	_
21	Groups	group	NNS	NNS	_	20	pobj	_	_
22	B	b	NN	NN	_	21	dep	_	_
23	and	and	CC	CC	_	22	cc	_	_
24	C	c	NN	NN	_	22	conj	_	_
25	-LRB-	-lrb-	-LRB-	-LRB-	_	27	punct	_	_
26	p	p	NN	NN	_	27	nsubj	_	_
27	=	=	JJ	JJ	_	22	dep	_	_
28	0.764	0.764	CD	CD	_	27	dobj	_	_
29	-RRB-	-rrb-	-RRB-	-RRB-	_	27	punct	_	_
30	.	.	.	.	_	7	punct	_	_

1	A	a	DT	DT	_	2	det	_	_
2	total	total	NN	NN	_	11	nsubj	_	_
3	of	of	IN	IN	_	2	prep	_	_
4	74	74	CD	CD	_	5	num	_	_
5	patients	patient	NNS	NNS	_	3	pobj	_	_
6	-LRB-	-lrb-	-LRB-	-LRB-	_	8	punct	_	_
7	88	88	CD	CD	_	8	num	_	_
8	%	%	NN	NN	_	5	appos	_	_
9	-RRB-	-rrb-	-RRB-	-RRB-	_	8	punct	_	_
10	were	be	VBD	VBD	_	11	cop	_	_
11	free	free	JJ	JJ	_	0	ROOT	_	_
12	from	from	IN	IN	_	11	prep	_	_
13	symptoms	symptom	NNS	NNS	_	12	pobj	_	_
14	at	at	IN	IN	_	13	prep	_	_
15	the	the	DT	DT	_	16	det	_	_
16	end	end	NN	NN	_	14	pobj	_	_
17	of	of	IN	IN	_	16	prep	_	_
18	the	the	DT	DT	_	20	det	_	_
19	triple	triple	JJ	JJ	_	20	amod	_	_
20	therapy	therapy	NN	NN	_	17	pobj	_	_
21	.	.	.	.	_	11	punct	_	_

1	Symptom	symptom	NN	NN	_	2	nn	_	_
2	relief	relief	NN	NN	_	4	nsubj	_	_
3	was	be	VBD	VBD	_	4	cop	_	_
4	faster	faster	RBR	RBR	_	0	ROOT	_	_
5	in	in	IN	IN	_	4	prep	_	_
6	patients	patient	NNS	NNS	_	5	pobj	_	_
7	with	with	IN	IN	_	6	prep	_	_
8	PPI-based	ppi-based	JJ	JJ	_	10	amod	_	_
9	triple	triple	JJ	JJ	_	10	amod	_	_
10	therapy	therapy	NN	NN	_	7	pobj	_	_
11	-LRB-	-lrb-	-LRB-	-LRB-	_	13	punct	_	_
12	Groups	group	NNS	NNS	_	13	nn	_	_
13	B	b	NN	NN	_	10	dep	_	_
14	and	and	CC	CC	_	13	cc	_	_
15	C	c	NN	NN	_	13	conj	_	_
16	-RRB-	-rrb-	-RRB-	-RRB-	_	13	punct	_	_
17	-LRB-	-lrb-	-LRB-	-LRB-	_	18	punct	_	_
18	days	day	NNS	NNS	_	4	dep	_	_
19	3	3	CD	CD	_	18	num	_	_
20	and	and	CC	CC	_	18	cc	_	_
21	4	4	CD	CD	_	18	conj	_	_
22	-RRB-	-rrb-	-RRB-	-RRB-	_	18	punct	_	_
23	than	than	IN	IN	_	4	prep	_	_
24	for	for	IN	IN	_	23	pcomp	_	_
25	patients	patient	NNS	NNS	_	24	pobj	_	_
26	with	with	IN	IN	_	25	prep	_	_
27	bismuth-based	bismuth-based	JJ	JJ	_	29	amod	_	_
28	triple	triple	JJ	JJ	_	29	amod	_	_
29	therapy	therapy	NN	NN	_	26	pobj	_	_
30	-LRB-	-lrb-	-LRB-	-LRB-	_	31	punct	_	_
31	day	day	NN	NN	_	4	dep	_	_
32	5	5	CD	CD	_	31	num	_	_
33	-RRB-	-rrb-	-RRB-	-RRB-	_	31	punct	_	_
34	.	.	.	.	_	4	punct	_	_

1	The	the	DT	DT	_	2	det	_	_
2	cost	cost	NN	NN	_	8	nsubj	_	_
3	of	of	IN	IN	_	2	prep	_	_
4	Group	Group	NNP	NNP	_	6	nn	_	_
5	C	C	NNP	NNP	_	6	nn	_	_
6	therapy	therapy	NN	NN	_	3	pobj	_	_
7	was	be	VBD	VBD	_	8	cop	_	_
8	lower	lower	JJR	JJR	_	0	ROOT	_	_
9	than	than	IN	IN	_	8	prep	_	_
10	that	that	DT	DT	_	9	pobj	_	_
11	for	for	IN	IN	_	10	prep	_	_
12	Groups	group	NNS	NNS	_	11	pobj	_	_
13	A	a	DT	DT	_	12	dep	_	_
14	and	and	CC	CC	_	13	cc	_	_
15	B.	B.	NNP	NNP	_	13	conj	_	_

1	There	there	EX	EX	_	2	expl	_	_
2	were	be	VBD	VBD	_	0	ROOT	_	_
3	no	no	DT	DT	_	5	neg	_	_
4	major	major	JJ	JJ	_	5	amod	_	_
5	side-effects	side-effect	NNS	NNS	_	2	nsubj	_	_
6	in	in	IN	IN	_	2	prep	_	_
7	any	any	DT	DT	_	6	pobj	_	_
8	of	of	IN	IN	_	7	prep	_	_
9	the	the	DT	DT	_	10	det	_	_
10	patients	patient	NNS	NNS	_	8	pobj	_	_
11	.	.	.	.	_	2	punct	_	_

1	One-week	one-week	JJ	JJ	_	3	amod	_	_
2	triple	triple	JJ	JJ	_	3	amod	_	_
3	therapy	therapy	NN	NN	_	12	nsubjpass	_	_
4	with	with	IN	IN	_	3	prep	_	_
5	omeprazole	omeprazole	NN	NN	_	4	pobj	_	_
6	,	,	,	,	_	5	punct	_	_
7	clarithromycin	clarithromycin	NN	NN	_	5	conj	_	_
8	and	and	CC	CC	_	5	cc	_	_
9	metronidazole	metronidazole	NN	NN	_	5	conj	_	_
10	is	be	VBZ	VBZ	_	12	auxpass	_	_
11	highly	highly	RB	RB	_	12	advmod	_	_
12	effected	effect	VBN	VBN	_	0	ROOT	_	_
13	for	for	IN	IN	_	12	prep	_	_
14	the	the	DT	DT	_	15	det	_	_
15	eradication	eradication	NN	NN	_	13	pobj	_	_
16	of	of	IN	IN	_	15	prep	_	_
17	H	h	NN	NN	_	18	nn	_	_
18	pylori	pylori	NN	NN	_	16	pobj	_	_
19	.	.	.	.	_	12	punct	_	_

1	A	a	DT	DT	_	3	det	_	_
2	therapeutic	therapeutic	JJ	JJ	_	3	amod	_	_
3	regime	regime	NN	NN	_	19	nsubj	_	_
4	of	of	IN	IN	_	3	prep	_	_
5	one	one	CD	CD	_	6	num	_	_
6	week	week	NN	NN	_	8	poss	_	_
7	's	's	POS	POS	_	6	possessive	_	_
8	duration	duration	NN	NN	_	4	pobj	_	_
9	with	with	IN	IN	_	3	prep	_	_
10	lower	lower	JJR	JJR	_	11	amod	_	_
11	cost	cost	NN	NN	_	9	pobj	_	_
12	,	,	,	,	_	3	punct	_	_
13	good	good	JJ	JJ	_	14	amod	_	_
14	compliance	compliance	NN	NN	_	3	appos	_	_
15	and	and	CC	CC	_	14	cc	_	_
16	mild	mild	JJ	JJ	_	17	amod	_	_
17	side-effects	side-effect	NNS	NNS	_	14	conj	_	_
18	may	may	MD	MD	_	19	aux	_	_
19	offer	offer	VB	VB	_	0	ROOT	_	_
20	a	a	DT	DT	_	22	det	_	_
21	good	good	JJ	JJ	_	22	amod	_	_
22	choice	choice	NN	NN	_	19	dobj	_	_
23	for	for	IN	IN	_	22	prep	_	_
24	treatment	treatment	NN	NN	_	23	pobj	_	_
25	of	of	IN	IN	_	24	prep	_	_
26	duodenal	duodenal	JJ	JJ	_	27	amod	_	_
27	ulcer	ulcer	NN	NN	_	25	pobj	_	_
28	associated	associate	VBN	VBN	_	27	vmod	_	_
29	with	with	IN	IN	_	28	prep	_	_
30	H	h	NN	NN	_	32	nn	_	_
31	pylori	pylori	NN	NN	_	32	nn	_	_
32	infection	infection	NN	NN	_	29	pobj	_	_
33	in	in	IN	IN	_	32	prep	_	_
34	clinical	clinical	JJ	JJ	_	35	amod	_	_
35	practice	practice	NN	NN	_	33	pobj	_	_
36	.	.	.	.	_	19	punct	_	_
